



NDA 205718/S-003

**SUPPLEMENT APPROVAL  
FULFILLMENT OF POSTMARKETING COMMITMENT**

Helsinn Healthcare SA  
Attention: Craig Lehmann  
August Consulting, Inc.  
515 Capital of Texas Highway, Suite 150  
Austin, TX 78746

Dear Mr. Lehmann:

Please refer to your Supplemental New Drug Application (sNDA) dated and received October 30, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Akynzeo (netupitant-palonosetron hydrochloride) capsules.

This "Prior Approval" supplemental new drug application proposes to update the Pharmacokinetics, Drug Interactions section of the package insert to reflect data from in vitro study reports NETU-14-30 and NETU-13-47; both submitted in support of fulfilling postmarketing commitment 2769-5.

**APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **FULFILLMENT OF POSTMARKETING COMMITMENT**

We have received your submission dated October 30, 2014, reporting on the following postmarketing commitment listed in the October 10, 2014, approval letter.

2769-5 In vitro study to evaluate the potential of netupitant to act as a substrate for P-gp transporter in a bi-directional transport assay system.

We have reviewed your submission and conclude that the above commitment was fulfilled.

We remind you that there are postmarketing commitment listed in the October 10, 2014, approval letter that are still open.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Heather Buck, Regulatory Project Manager, at (301) 796-1413.

Sincerely,

*{See appended electronic signature page}*

Joyce Korvick, M.D., M.P.H.  
Deputy Director for Safety  
Division of Gastroenterology and Inborn Errors Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
JOYCE A KORVICK  
04/27/2015